Drugs /

transurethral resection of bladder tumor

Back to Drugs List

Overview

NCI Definition [1]:
A surgical procedure used to treat bladder tumors, during which a resectoscope is passed through the urethra and into the bladder.

Clinical Trials

View Clinical Trials for transurethral resection of bladder tumor

Transurethral resection of bladder tumor has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating transurethral resection of bladder tumor, 1 is phase 2 (1 open).

ARID1A Loss, ARID1A Mutation, and ATM Loss are the most frequent biomarker inclusion criteria for transurethral resection of bladder tumor clinical trials.

Bladder urothelial carcinoma is the most common disease being investigated in transurethral resection of bladder tumor clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Transurethral Resection Of Bladder Tumor
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating transurethral resection of bladder tumor and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
turbt, transurethral resection (turbt)
NCIT ID [1]:
C116651

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.